EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Differential Expression of Immune Checkpoints TIM-3, LAG-3, TIGIT, and Siglec-7 on Circulating Natural Killer Cells – Insights from Healthy Donors Compared to Gastric Cancer Patients

Sabine Seiffert, Sabine Seiffert, André-René Blaudszun, Benjamin Shibru, Justus Körfer, Ulrike Köhl, Stephan Fricke, Ulrich Sack, Andreas Boldt

Oncology Research and Treatment · 03.04.2025 · 48 (10) · 585-600

DOI: 10.1159/000545429 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Oncology Research and Treatment, online erschienen am 03.04.2025. Verfasst von Sabine Seiffert und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Immunology, University of Leipzig, Leipzig, Germany. Hauptthemen laut MEDLINE: Stomach Neoplasms, Killer Cells, Natural, Hepatitis A Virus Cellular Receptor 2, Receptors, Immunologic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The complex, multifactorial nature of gastric cancer presents significant challenges in the development of effective immunotherapies. Targeting immune checkpoints has emerged as a promising strategy, with blockade therapies demonstrating clinical success. However, resistance in a subset of patients emphasizes the need for alternative approaches. Exploration of novel immune checkpoints, particularly on natural killer (NK) cells, could enhance the efficacy and potency of immunotherapy, offering new avenues for overcoming resistance and improving patient outcomes. NK cells are crucial in the primary defense against viral infections, tumor development, and metastasis. The cytotoxic function of NK cells is finely regulated by a complex array of activating and inhibitory receptors, including checkpoint receptors. Malignantly transformed cells can impair NK-cell activity by expressing soluble or membrane-bound checkpoint ligands, thereby modulating immune responses to support tumor progression.

Methods

To investigate this dilemma, we simulated in vitro activation by NK-cell co-incubation with K562 cells and analyzed expression of TIM-3, LAG-3, TIGIT, and Siglec-7. After that, we analyzed the checkpoint expression of circulating NK cells from 35 healthy donors and compared it to their expression in patients with gastric cancer (n = 21) using flow cytometry.

Results

In healthy donors, we observed that 25–97% of all circulating NK cells expressed TIM-3, TIGIT and Siglec-7, while only a small fraction of 0.6% expressed LAG-3. Co-incubation of peripheral blood mononuclear cells from healthy donors with K562 cells resulted in heightened expression levels of TIM-3 and TIGIT on NK cells. Conversely, NK cells in patients with gastric cancer showed an increased LAG-3 and reduced Siglec-7 expression.

Conclusion

Our findings suggest the potential of LAG-3 as a next-generation checkpoint molecule, alongside Siglec-7. Especially targeting the sialic acid-Siglec-7 axis may offer promising therapeutic strategies for various cancer types in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsKiller Cells, NaturalHepatitis A Virus Cellular Receptor 2Receptors, ImmunologicAntigens, CDLectinsHumansLymphocyte Activation Gene 3 ProteinMaleFemaleMiddle AgedK562 CellsAgedAdultCase-Control StudiesAntigens, Differentiation, Myelomonocytic

Stichwörter der Autor:innen

Checkpoint receptorsCirculating NK cellsGastric cancer

Substanzen

TIGIT protein, humanHepatitis A Virus Cellular Receptor 2SIGLEC7 protein, humanHAVCR2 protein, humanLag3 protein, humanReceptors, ImmunologicLymphocyte Activation Gene 3 ProteinAntigens, CDLectinsAntigens, Differentiation, Myelomonocytic

Autor:innen und Institutionen

  • Institute of Clinical Immunology, University of Leipzig, Leipzig, Germany.
  • Fraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany.
  • Department for Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, University of Leipzig Medical Center, Leipzig, Germany.
  • Practice for Oncology and Hematology, Peine, Germany.
  • MEDiC Campus Chemnitz of TUD Dresden University of Technology at Klinikum Chemnitz gGmbH, Chemnitz, Germany.

Zitieren

APA

Seiffert, S., Seiffert, S., Blaudszun, A. R., Shibru, B., Körfer, J., Köhl, U., Fricke, S., Sack, U., & Boldt, A. (2025). Differential Expression of Immune Checkpoints TIM-3, LAG-3, TIGIT, and Siglec-7 on Circulating Natural Killer Cells – Insights from Healthy Donors Compared to Gastric Cancer Patients. Oncology Research and Treatment, 48(10), 585-600. https://doi.org/10.1159/000545429

Vancouver

Seiffert S, Seiffert S, Blaudszun AR, Shibru B, Körfer J, Köhl U, et al. Differential Expression of Immune Checkpoints TIM-3, LAG-3, TIGIT, and Siglec-7 on Circulating Natural Killer Cells – Insights from Healthy Donors Compared to Gastric Cancer Patients. Oncology Research and Treatment. 2025;48(10):585-600. doi:10.1159/000545429

BibTeX
@article{Seiffert2025,
  author = {Seiffert, Sabine and Seiffert, Sabine and Blaudszun, André-René and Shibru, Benjamin and Körfer, Justus and Köhl, Ulrike and Fricke, Stephan and Sack, Ulrich and Boldt, Andreas},
  title = {Differential Expression of Immune Checkpoints TIM-3, LAG-3, TIGIT, and Siglec-7 on Circulating Natural Killer Cells – Insights from Healthy Donors Compared to Gastric Cancer Patients},
  journal = {Oncology Research and Treatment},
  year = {2025},
  volume = {48},
  number = {10},
  pages = {585--600},
  doi = {10.1159/000545429}
}
Kostenlos starten →